


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (currently amended): A compound of formula (I):



(I)

wherein:

X is C₁₋₆ alkylene or C₂₋₆ alkenylene, each of which is optionally substituted by one or more fluorine atoms;

R is aryl or C₃₋₈ cycloalkyl optionally substituted by one or more fluorine atoms;

W is N or CZ;

Y is

(a) NR¹R³,

(b) C₁₋₄ alkyl substituted by NR¹R² or by a 4- to 7-membered N-heterocycle attached via the N-atom, which heterocycle optionally contains 1 or 2 further ring hetero-atoms independently selected from N, O and S, and which heterocycle is

optionally substituted by one or more substituents independently selected from R^2 , =O and OH,

or (c) a 4- to 7-membered saturated or partially or fully unsaturated N-heterocycle, which heterocycle optionally contains 1 or 2 further ring hetero-atoms independently selected from N, O and S, and which heterocycle is optionally substituted by one or more substituents independently selected from R^2 , =O and OH,

Z is H or C_{1-4} alkyl,

or when W is CZ, Y can be H or C_{1-4} alkyl, and Z can be

(a) NR^1R^3 ,

(b) C_{1-4} alkyl substituted by NR^1R^2 or by a 4- to 7-membered N-heterocycle attached via the N-atom, which heterocycle optionally contains 1 or 2 further ring hetero-atoms independently selected from N, O and S, and which heterocycle is optionally substituted by one or more substituents independently selected from R^2 , =O and OH,

or (c) a 4- to 7-membered saturated or partially or fully unsaturated N-heterocycle attached via the N-atom, which heterocycle optionally contains 1 or 2 further ring hetero-atoms independently selected from N, O and S, and which heterocycle is optionally substituted by one or more substituents independently selected from R^2 , =O and OH,

R^2 is H,

C_{1-6} alkyl (optionally substituted by one or more substituents independently selected from OH, C_{1-4} alkoxy, $C(O)_p(C_{1-4}$ alkyl, aryl, heteroaryl, or NR^1R^3), $CONR^1R^3$ or NR^1R^3),

$SO_2(C_{1-4}$ alkyl, aryl, heteroaryl or NR^1R^3),

$C(O)_p(C_{1-4}$ alkyl optionally substituted by C_{1-4} alkoxy or NR^1R^3),

$C(O)_p(C_{3-7}$ cycloalkyl),

$C(O)_p(\text{aryl})$,

$C(O)_p(\text{heteroaryl})$,

$CONR^1R^3$,

C_{3-7} cycloalkyl optionally substituted by one or more substituents independently selected from OH and C_{1-4} alkoxy,

a 4- to 7-membered saturated or partially or fully unsaturated heterocycle, which heterocycle ring contains up to 3 ring hetero-atoms independently selected from N, O and S, and which heterocycle is optionally substituted by one or more substituents independently selected from R^3 , =O, OH, $SO_2(C_{1-4} \text{ alkyl})$ and/or $C(O)_p(C_{1-4} \text{ alkyl})$ groups,

or aryl,

R^1 and R^3 are each independently selected from H and (C_{1-4} alkyl optionally substituted by OH, NR^4R^5 or by C_{1-4} alkoxy),

R^4 and R^5 are each independently selected from H and C_{1-4} alkyl,


p is 1 or 2,

"aryl" is phenyl optionally substituted by one or more substituents independently selected from R^3 , OH, $SO_2(C_{1-4} \text{ alkyl})$ and/or $C(O)_p(C_{1-4} \text{ alkyl})$ groups,

"heteroaryl" is a 5- to 7-membered aromatic heterocycle with 1, 2 or 3 ring hetero-atoms independently selected from N, O and S, and which ring is optionally substituted by one or more substituents independently selected from R^3 , =O, OH, $SO_2(C_{1-4} \text{ alkyl})$ and/or $C(O)_p(C_{1-4} \text{ alkyl})$ groups,

or a and the pharmaceutically acceptable salts, solvates (including hydrates) or and prodrugs thereof.

Claim 2 (original): A compound, salt, solvate or prodrug according to claim 1 wherein the compound of formula (I) has the following stereochemistry (IA):



Claim 3 (original): A compound, salt, solvate or prodrug according to claim 1 wherein W is N.

Claim 4 (original): A compound, salt, solvate or prodrug according to claim 1 wherein X is a linear C₂₋₆ alkylene moiety optionally substituted by one or more fluorine atoms.

Claim 5 (original): A compound, salt, solvate or prodrug according to claim 1 wherein R is C₃₋₈ cycloalkyl optionally substituted by one or more fluorine atoms.

Claim 6 (original): A compound, salt, solvate or prodrug according to claim 1 wherein Y is C₁₋₄ alkyl substituted by NR¹R², or Y is a 4- to 7-membered saturated or partially or fully unsaturated N-heterocycle, which heterocycle optionally contains 1 or 2 further ring hetero-atoms independently selected from N, O and S, and which heterocycle is optionally substituted by one or more substituents independently selected from R², =O and OH.

Claim 7 (original): A compound, salt, solvate or prodrug according to claim 1 wherein W is CZ and Z is H or CH₃.

Claim 8 (original): A compound, salt, solvate or prodrug according to claim 1 wherein X is propylene.

Claim 9 (original): A compound, salt, solvate or prodrug according to claim 1 wherein R is cyclobutyl, cyclopentyl or cyclohexyl optionally substituted by one or more fluorine atoms.

Claim 10 (original): A compound, salt, solvate or prodrug according to claim 1 wherein Y is CH₂ substituted by NR¹R², or Y is a 6-membered saturated or partially or fully unsaturated N-heterocycle, and which heterocycle is optionally substituted by one or more substituents independently selected from R², =O and OH.

Claim 11 (original): A compound, salt, solvate or prodrug according to claim 1 wherein R is cyclohexyl.

Claim 12 (original): A compound, salt, solvate or prodrug according to claim 1 wherein Y is CH₂N(H or CH₃)(SO₂(C₁₋₄ alkyl, aryl, heteroaryl or NR¹R³)), or Y is a 6-membered saturated or partially or fully unsaturated N-heterocycle, and which heterocycle is optionally substituted by SO₂(C₁₋₄ alkyl) and/or C(O)_p(C₁₋₄ alkyl) groups.

Claim 13 (original): A compound, salt, solvate or prodrug according to claim 1 wherein Y is CH₂NHSO₂(C₁₋₄ alkyl), or Y is a 6-membered saturated N-heterocycle, and which heterocycle is optionally substituted by SO₂(C₁₋₄ alkyl) or C(O)_p(C₁₋₄ alkyl).

Claim 14 (original): A compound, salt, solvate or prodrug according to claim 1 wherein Y is $\text{CH}_2\text{NHSO}_2\text{CH}_3$ or methylsulphonylpiperidinyl.

Claim 15 (original): A compound selected from any of the Examples disclosed herein, or a salt, solvate or prodrug thereof.

Claim 16 (original): A pharmaceutical composition comprising a compound, salt, solvate or prodrug according to claim 1 and a pharmaceutically acceptable adjuvant, diluent or carrier.

Claim 17 (original): A kit comprising :
a compound, salt, solvate or prodrug according to claim 1, packaging; and
instructions for the use of the said compound, salt, solvate, prodrug or
composition in a manner suitable for treating or preventing a condition mediated
by PCP.

Claim 18 (original): A compound, salt, solvate or prodrug according to of claim 1
for use in treating or preventing a condition mediated by PCP.

Claim 19 (original): A method of treating or preventing a condition mediated by
PCP which comprises administration of an effective amount of a compound, salt,
solvate or prodrug according to claim 1 to a patient in need thereof.